Jean-Paul Briand

This inventor holds 18 USPTO granted patents and 4 published patent applications, plus 9 CIPO patents and 4 EPO patents. Top assignees: Centre National De La Recherche Scientifique, Immupharma France Sa, Biomerieux Sa. Active years: 1988-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Paul Briand. Retrieved from https://idiyas.com/inventor/jean-paul-briand

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 4)

% Patents Active = 77.8

CIPO Patents = 9

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 4.2

ph-index = 5

Forward Citations = 76(Granted Patents)

Company Filing History:

12 out of 5,383

Centre National De La Recherche Scientifique

Pasteur Sanofi Diagnostics

patents

where one patent can have more than one assignee

Years Active: 1988-2019

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10213482 - Methods of treating chronic inflammatory diseases (2019-02-26),

2. 9657072 - Modified peptides and their use for treating autoimmune diseases (2017-05-23),

3. 8475800 - Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies (2013-07-02),

4. 8173767 - Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV (2012-05-08),

5. 8138145 - Hybrid oligomers, their preparation process and pharmaceutical compositions containing them (2012-03-20),

6. 8071640 - Urea oligomers, their preparation process and pharmaceutical compositions containing them (2011-12-06),

7. 7872098 - Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies (2011-01-18),

8. 7691899 - Urea oligomers, the preparation method thereof and pharmaceutical composition containing same (2010-04-06),

9. 7691807 - Hybrid oligomers, their preparation process and pharmaceutical compositions containing them (2010-04-06),

10. 7364744 - Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV (2008-04-29),

11. 7199215 - Pseudopeptide, synthesis method, reagent and applications (2007-04-03),

12. 7186828 - Cyclic urea compounds and preparation thereof (2007-03-06),

13. 7186739 - Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas (2007-03-06),

14. 7122193 - Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis (2006-10-17),

15. 7060845 - Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas (2006-06-13),

Title: Jean-Paul Briand: Innovator in Chronic Inflammatory Disease Treatments

Introduction: Jean-Paul Briand is a distinguished inventor based in Strasbourg, France, recognized for his significant contributions to medical science. With an impressive total of 18 patents to his name, he has been instrumental in developing innovative treatments for chronic inflammatory diseases. His expertise in peptide technology has positioned him at the forefront of biomedical research.

Latest Patents: Among Jean-Paul Briand's latest patents are groundbreaking inventions focusing on methods of treating chronic inflammatory diseases. One of his notable inventions involves a peptide, or a salt thereof, that comprises the amino acid sequence IHMVYSKRSGKPRGYAFIEY, with potential applications in the treatment, prevention, or amelioration of hyper autophagy-related autoimmune diseases or disorders. Additionally, he has developed modified peptides and their uses for treating various autoimmune diseases, showcasing his commitment to advancing therapeutic options.

Career Highlights: Throughout his career, Jean-Paul Briand has been associated with prestigious organizations, including the Centre National de la Recherche Scientifique and Immupharma France Sa. His tenure at these institutions has allowed him to collaborate with some of the brightest minds in the field, contributing to innovative research and development.

Collaborations: In his pursuit of innovation, Jean-Paul Briand has worked closely with esteemed colleagues such as Gilles Guichard and Sylviane Muller. These collaborations have resulted in significant advancements in the understanding and treatment of autoimmune conditions, underscoring the importance of teamwork in scientific progress.

Conclusion: Jean-Paul Briand's work as an inventor has made a substantial impact on the field of medicine, particularly in the realm of chronic inflammatory disease treatment. His dedication to research and innovation has led to the development of valuable patents that hold promise for improving patient outcomes. As he continues to push the boundaries of science, his contributions will undoubtedly inspire future innovations in healthcare.

Profile summary based on public USPTO records.